1. Home
  2. GGZ vs ANIX Comparison

GGZ vs ANIX Comparison

Compare GGZ & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest

GGZ

Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest

HOLD

Current Price

$15.06

Market Cap

129.0M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.66

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGZ
ANIX
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.0M
114.0M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
GGZ
ANIX
Price
$15.06
$2.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $9.75
AVG Volume (30 Days)
4.8K
★ 267.0K
Earning Date
01-01-0001
09-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.82
EPS
★ N/A
N/A
Revenue
N/A
★ $210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.35
$2.32
52 Week High
$17.08
$5.46

Technical Indicators

Market Signals
Indicator
GGZ
ANIX
Relative Strength Index (RSI) 35.48 40.61
Support Level $14.64 $2.62
Resistance Level $15.53 $3.09
Average True Range (ATR) 0.18 0.14
MACD -0.01 -0.01
Stochastic Oscillator 4.85 10.42

Price Performance

Historical Comparison
GGZ
ANIX

About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest

The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: